First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma

A. Helland; V. D. Haakensen; A. K. Ojlert; S. M. H. Thunold; A. K. Nowak; W. L. Chin; O. Grundberg; S. J. Farooqi; M. Lund-Iversen; W. M. Szejniuk; S. M. C. Perez; J. B. Sørensen; M. M. Bjaanaes

doi:10.1016/j.annonc.2023.10.102

First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma

A. Helland, V. D. Haakensen, A. K. Ojlert, S. M. H. Thunold, A. K. Nowak, W. L. Chin, O. Grundberg, S. J. Farooqi, M. Lund-Iversen, W. M. Szejniuk, S. M. C. Perez, J. B. Sørensen, M. M. Bjaanaes

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	LBA99
Journal	Annals of Oncology
Volume	34
Issue number	Suppl. 2
Pages (from-to)	S1337
Number of pages	1
ISSN	0923-7534
DOIs	https://doi.org/10.1016/j.annonc.2023.10.102
Publication status	Published - Oct 2023
Event	ESMO Congress 2023 - Madrid, Spain Duration: 20 Oct 2023 → 24 Oct 2023 https://www.esmo.org/meeting-calendar/past-meetings/esmo-congress-2023

Conference

Conference	ESMO Congress 2023
Country/Territory	Spain
City	Madrid
Period	20/10/2023 → 24/10/2023
Internet address	https://www.esmo.org/meeting-calendar/past-meetings/esmo-congress-2023

Bibliographical note

Abstract No. LBA99

Access to Document

10.1016/j.annonc.2023.10.102

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Helland, A., Haakensen, V. D., Ojlert, A. K., Thunold, S. M. H., Nowak, A. K., Chin, W. L., Grundberg, O., Farooqi, S. J., Lund-Iversen, M., Szejniuk, W. M., Perez, S. M. C., Sørensen, J. B., & Bjaanaes, M. M. (2023). First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma. Annals of Oncology, 34(Suppl. 2), S1337. Article LBA99. https://doi.org/10.1016/j.annonc.2023.10.102

@article{86984fd7dcea45db8494e05201b37ac3,

title = "First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma",

author = "A. Helland and Haakensen, {V. D.} and Ojlert, {A. K.} and Thunold, {S. M. H.} and Nowak, {A. K.} and Chin, {W. L.} and O. Grundberg and Farooqi, {S. J.} and M. Lund-Iversen and Szejniuk, {W. M.} and Perez, {S. M. C.} and S{\o}rensen, {J. B.} and Bjaanaes, {M. M.}",

note = "Abstract No. LBA99; ESMO Congress 2023 ; Conference date: 20-10-2023 Through 24-10-2023",

year = "2023",

month = oct,

doi = "10.1016/j.annonc.2023.10.102",

language = "English",

volume = "34",

pages = "S1337",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Suppl. 2",

url = "https://www.esmo.org/meeting-calendar/past-meetings/esmo-congress-2023",

}

Helland, A, Haakensen, VD, Ojlert, AK, Thunold, SMH, Nowak, AK, Chin, WL, Grundberg, O, Farooqi, SJ, Lund-Iversen, M, Szejniuk, WM, Perez, SMC, Sørensen, JB & Bjaanaes, MM 2023, 'First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma', Annals of Oncology, vol. 34, no. Suppl. 2, LBA99, pp. S1337. https://doi.org/10.1016/j.annonc.2023.10.102

First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma. / Helland, A.; Haakensen, V. D.; Ojlert, A. K. et al.
In: Annals of Oncology, Vol. 34, No. Suppl. 2, LBA99, 10.2023, p. S1337.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma

AU - Helland, A.

AU - Haakensen, V. D.

AU - Ojlert, A. K.

AU - Thunold, S. M. H.

AU - Nowak, A. K.

AU - Chin, W. L.

AU - Grundberg, O.

AU - Farooqi, S. J.

AU - Lund-Iversen, M.

AU - Szejniuk, W. M.

AU - Perez, S. M. C.

AU - Sørensen, J. B.

AU - Bjaanaes, M. M.

N1 - Abstract No. LBA99

PY - 2023/10

Y1 - 2023/10

U2 - 10.1016/j.annonc.2023.10.102

DO - 10.1016/j.annonc.2023.10.102

M3 - Conference abstract in journal

SN - 0923-7534

VL - 34

SP - S1337

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 2

M1 - LBA99

T2 - ESMO Congress 2023

Y2 - 20 October 2023 through 24 October 2023

ER -

Helland A, Haakensen VD, Ojlert AK, Thunold SMH, Nowak AK, Chin WL et al. First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma. Annals of Oncology. 2023 Oct;34(Suppl. 2):S1337. LBA99. doi: 10.1016/j.annonc.2023.10.102